FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT	OF	CHANGES	IN I	BENEFICIA	L O	WNERS	HIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Teehan Brendan (Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC.						Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC ACAD 3. Date of Earliest Transaction (Month/Day/Year) 04/29/2023										eck all appli Directo X Officer below)	cable) or (give title	g Person(s) to Iss 10% O Other (s below) ad of Commerce		wner (specify
		RMACEUTICA REAL, SUITE			4. It	f Ame	ndmer	nt, Date	of Ori	riginal F	iled	(Month/D	ay/Yea	ır)	Line	6. Individual or Joint/Group Filing (Check Appl Line) X Form filed by One Reporting Person				
(Street) SAN DII	EGO C.	A	92130														iled by Mor		orting Person One Repo	
(City)	(S	tate)	(Zip)		Ru	Chec	k this b	oox to inc	dicate	that a tr	ansa	ion Ind	made p	ursuan			on or written	plan t	hat is intende	d to
		Tab	le I - No	n-Deriv	/ative	Sec	curit	ies Ac	qui	ired, [Dis	posed o	of, or	Ben	eficial	ly Owne	t			
Date			Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		, т С	3. Transaction Disposed Code (Instr. 8)						Benefic Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									C	Code	v	Amount	()	A) or D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Stock 04/29				9/2023	2023				M		1,567	7	A	\$0.00) 10	10,035		D		
Common	Stock			05/01	1/2023	3				S ⁽¹⁾		548		D	\$21.1	\$21.18 9,487 D				
		Т										osed of onverti				Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercis Price of Derivative Security		3. Transaction Date (Month/Day/Year) AM. Deen Executio if any (Month/D		Date, Transacti Code (Ins					6. Date Exercisis Expiration Date (Month/Day/Yea			7. Title and Amount of Securities Underlying Derivative Se (Instr. 3 and 4			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title		or Number of Shares					
Restricted Stock	(2)	04/29/2023			M			1,567		(3)		(3)	Comr		1,567	\$0.00	0		D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- 2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 3. 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023.

Remarks:

/s/ Austin D. Kim, Attorney-in-

Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.